Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Business Insider16d
Vertex Pharmaceuticals exec Altshuler sells 3,231 common shares
In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the company on March 13 at a price of $510 per share.
The Motley Fool23d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
WAAY-TV27d
Wreck on Hwy 231 in Lacey's Spring diverts traffic to Old Hwy 231
The Morgan County Sheriff's Office say a wreck on Highway 231 at Old Highway 231 in Lacey's Spring caused traffic to be rerouted Friday night. The sheriff's office said shortly after 7:30 p.m ...
BioPharma Dive28d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, a pharmacy benefit manager owned by one of the country’s largest insurance companies, UnitedHealth Group, has added a new, much-anticipated pain drug to some of its commercial formularies.